로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2 Hot
0
장바구니가 비어 있습니다
내 장바구니
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: 홈 > Protein > CD20 > CD0-CF2H3

FITC-Labeled Cynomolgus CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc)

INTRODUCTION
QC & Assay Protocol
Citation & Background
  • Synonym
    MS4A1,CD20,MS4A-1
  • Source
    FITC-Labeled Cynomolgus CD20 Full Length Protein, His Tag(CD0-CF2H3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # M4ZHZ6-1 ).
    Predicted N-terminus: Met 1
    Request for sequence
  • Molecular Characterization

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 35.2 kDa.

    Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by a membrane scaffold protein (MSP1D1) coat that confers enhanced stability and a narrow particle size distribution.

    The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein(MSP1D1) upon removal of the detergent.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Labeling
    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >85% as determined by SDS-PAGE.

  • Formulation

    Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
*The isotype control of empty/mock nanodisc (Cat. No. APO-H51H3) is sold separately and not included in protein, you can follow this link for product information.
Bioactivity-ELISA
CD20 ELISA

Immobilized FITC-Labeled Cynomolgus CD20 Full Length Protein, His Tag (Cat. No. CD0-CF2H3) at 2 μg/mL (100 μL/well) can bind Rituximab biosimilar with a linear range of 0.01-0.156 μg/mL (QC tested).

Protocol
  • Background
    B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 2,100,000

가격(KRW) : 7,800,000

장바구니에 담기 대량구매 맞춤형 제품

Antibody Licensing

more

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs：31 Details
  • Number of Drugs in Clinical Trials：103 Details
  • Latest Research Phase：Approved
다른 추천 제품

Datasheet & Documentation

DMF 신청
DMF (Drug Master File)

연락처

+1  800-810-0816 (US)
+86 400-682-2521 (AP)
Show All Distributors

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop
Call us
우리에게 전화하세요
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
Email
이메일
order.kr@acrobiosystems.com
Fax
팩스
+1 888-377-6111
Address
주소
서울 성동구 왕십리로10길 6 서울숲비즈포레 703
회사명
아크로바이오 주식회사
사업자 등록번호
186-88-02858
대표자
CHEN YIDING
사업장주소
서울특별시 송파구 중대로12길 10-20, 1층 셀렉티드송파(가락동)
linkedin twitter facebook youtube

문의

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap